Insider filing · CAMP

Amir Nashat bought $10.0M of CAMP4 THERAPEUTICS (CAMP)

Executed Oct 15 2024, disclosed Oct 15 2024, the same day.

Over the 21 trading sessions from the disclosed entry session (Oct 15 2024), the stock returned +20.8% (delay-adjusted); from the execution session (Oct 15 2024), +20.8%. Derived: entry at the session's open, exit at the close 20 sessions later.

AN Amir Nashat Director profile →

Amir Nashat (Director) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in CAMP4 THERAPEUTICS CORPORATION (CAMP). Across 2 priced purchase filings, the average 21-session return was +32.7% from execution and +32.7% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of CAMP (909,090 sh × $11.00, as filed), executed Oct 15 2024.

CAMP CAMP4 THERAPEUTICS CORPORATION CAMP · Healthcare · 13 filings in 24 months ticker →

Healthcare · Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→